REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress.
Fourth Quarter and Recent Corporate Progress:
•In February 2015, the Company initiated a Phase 1 single-ascending dose, placebo-controlled clinical trial of HTX-011 in healthy volunteers. This study is evaluating safety, pharmacokinetics, and pharmacodynamics of the anesthetic effects of the product.
Help employers find you! Check out all the jobs and post your resume.
